Epigenomics AG, which specialises in molecular diagnostics for cancer, has appointed Gregory Hamilton as chief executive officer, replacing Thomas Taapken, who has left the company after serving as both CEO and chief financial officer for four years.
Mr Hamilton, who has a master’s degree in business administration from the University of Chicago, has considerable management experience in diagnostics. He previously was chief executive of AltheaDX Inc, a diagnostics company focused on pharmacogenetics. Before that, he was chief operating officer and chief financial officer of Enigma Diagnostics Inc. Prior to this he held executive positions at Third Wave Technologies Inc and Hologic Inc.
Mr Hamilton’s appointment was announced on 30 June 2016.
Copyright 2016 Evernow Publishing Ltd